Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 9970001 Methods and compositions for nuclease design

Patent 9970001 was granted and assigned to Sangamo Therapeutics on May, 2018 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

Current Assignee

Sangamo Therapeutics

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

9970001

Patent Inventor Names

Jeffrey C. Miller0

Date of Patent

May 15, 2018

Patent Application Number

14731821

Date Filed

June 5, 2015

Patent Citations Received

‌

US Patent 11866726 Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites

‌

US Patent 12110545 Methods of assessing nuclease cleavage

‌

US Patent 11667911 Use of exonucleases to improve CRISPR/CAS-mediated genome editing

‌

US Patent 11680268 Methods for improving CRISPR/Cas-mediated genome-editing

‌

US Patent 11911415 CRISPR/Cas-related methods and compositions for improving transplantation

Patent Primary Examiner

‌

Kagnew H Gebreyesus

Patent abstract

Methods and compositions for genetic alteration of cells are provided.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 9970001 Methods and compositions for nuclease design

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API